[go: up one dir, main page]

WO2011046309A3 - A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof - Google Patents

A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof Download PDF

Info

Publication number
WO2011046309A3
WO2011046309A3 PCT/KR2010/006727 KR2010006727W WO2011046309A3 WO 2011046309 A3 WO2011046309 A3 WO 2011046309A3 KR 2010006727 W KR2010006727 W KR 2010006727W WO 2011046309 A3 WO2011046309 A3 WO 2011046309A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatocellular carcinoma
autoantibody
diagnostic
composition
fasn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/006727
Other languages
French (fr)
Other versions
WO2011046309A2 (en
Inventor
Eun-Wie Cho
Chang-Kyu Heo
Mi-Kyung Woo
Hai Min Hwang
Hyang-Sook Yoo
Jeong-Heun Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100018205A external-priority patent/KR101138460B1/en
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority to US13/501,426 priority Critical patent/US8658769B2/en
Publication of WO2011046309A2 publication Critical patent/WO2011046309A2/en
Publication of WO2011046309A3 publication Critical patent/WO2011046309A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.
PCT/KR2010/006727 2009-10-12 2010-10-01 A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof Ceased WO2011046309A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/501,426 US8658769B2 (en) 2009-10-12 2010-10-01 Diagnostic marker for hepatocellular carcinoma comprising anti-FASN autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20090096991 2009-10-12
KR10-2009-0096991 2009-10-12
KR10-2010-0018205 2010-02-26
KR1020100018205A KR101138460B1 (en) 2009-10-12 2010-02-26 A marker comprising anti-FASN autoantibodies and a composition comprising antigen thereof for diagnosing liver cancer

Publications (2)

Publication Number Publication Date
WO2011046309A2 WO2011046309A2 (en) 2011-04-21
WO2011046309A3 true WO2011046309A3 (en) 2011-09-15

Family

ID=43876666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006727 Ceased WO2011046309A2 (en) 2009-10-12 2010-10-01 A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof

Country Status (1)

Country Link
WO (1) WO2011046309A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101374758B1 (en) 2011-02-18 2014-03-17 한국생명공학연구원 A marker comprising anti-CK8/18 complex autoantibodies and a composition comprising antigen thereof for diagnosing cancer
KR101439856B1 (en) * 2011-06-02 2014-09-17 한국생명공학연구원 A marker comprising anti-ATIC autoantibodies and a composition comprising antigen thereof for diagnosing liver cancer
WO2013123152A2 (en) * 2012-02-17 2013-08-22 Seattle Genetics, Inc. ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
JP7437000B2 (en) * 2016-07-01 2024-02-22 パラクライン セラピューティクス アーベー Methods and compositions for inhibition of PDGF-CC
KR20220110231A (en) 2019-12-05 2022-08-05 씨젠 인크. Anti-αvβ6 Antibodies and Antibody-Drug Conjugates
KR102307043B1 (en) * 2019-12-10 2021-10-01 아주대학교산학협력단 Composition for early diagnosing hepatocellular carcinoma using WASF2 autoantibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103212A1 (en) * 1999-05-24 2002-08-01 Sankyo Company, Limited Pharmaceutical compositions containing anti-fas antibody
US20040024050A1 (en) * 2002-04-17 2004-02-05 Smith Jeffrey W. Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
US20070142456A1 (en) * 2002-10-31 2007-06-21 Fasgen, Llc Method for inhibiting cancer development by fatty acid synthase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103212A1 (en) * 1999-05-24 2002-08-01 Sankyo Company, Limited Pharmaceutical compositions containing anti-fas antibody
US20040024050A1 (en) * 2002-04-17 2004-02-05 Smith Jeffrey W. Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
US20070142456A1 (en) * 2002-10-31 2007-06-21 Fasgen, Llc Method for inhibiting cancer development by fatty acid synthase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HO ET AL.: "Fatty acid synthase inhibitors cerulenin and C75 retard growth a nd induce caspase-dependent apoptosis in human melanoma A-375 cells", BIOMED ICINE & PHARMACOTHERAPY, vol. 61, 14 September 2007 (2007-09-14), pages 578 - 587, XP022300640, DOI: doi:10.1016/j.biopha.2007.08.020 *
LEIDFELD ET AL.: "Anti-apoptotic function of gelsolin in FAS antibody-induce d liver failure in vivo", AM. J. PATHOLOGY, vol. 168, no. 3, 31 March 2006 (2006-03-31), pages 778 - 785 *

Also Published As

Publication number Publication date
WO2011046309A2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
EA201001874A1 (en) A METHOD FOR DIAGNOSTIC MALIGNANT NUMER FORMATION, EXPRESSING THE HER2 RECEPTOR OR HIS REDUCED OPTIONS
WO2011046309A3 (en) A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
WO2012059598A3 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
WO2012106556A3 (en) Methods and compositons relating to inhibition of igf-1r
WO2009113814A3 (en) Protein marker for early diagnosis of liver cancer
WO2012112013A3 (en) A marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer
WO2009083009A3 (en) Monoclonal antibodies against cd32b
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2010066803A3 (en) Human antibodies against human tissue factor
WO2012031122A3 (en) Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders
EP2582722A4 (en) ANTI-GD2 ANTIBODIES
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
NZ595340A (en) Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
WO2011156734A3 (en) Method of characterizing vascular diseases
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2012012750A8 (en) Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
WO2011015602A3 (en) Lung cancer biomarkers
NZ707116A (en) Ly75 as cancer therapeutic and diagnostic target
WO2012082742A3 (en) Detecting cancer with anti-ccl25 and anti-ccr9 antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10823551

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13501426

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10823551

Country of ref document: EP

Kind code of ref document: A2